How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) posted its earnings results on Monday, November, 8th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.09. During the same period in the prior year, the business posted ($1.55) EPS.

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com . Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE) , Sorrento Therapeutics (SRNE) , Gilead Sciences (GILD) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , Aldeyra Therapeutics (ALDX) , Atara Biotherapeutics (ATRA) , bluebird bio (BLUE) , Moderna (MRNA) and AT&T (T) .

When did Tricida IPO?

Tricida (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

NASDAQ:TCDA

Tricida (TCDA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TCDA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.11
▼
$0.19
52-Week Range: N/A

Volume: 31.13 million shs
Average Volume: 17.62 million shs
Market Capitalization: $6.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Tricida alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Tricida Stock (NASDAQ:TCDA)

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

TCDA Stock News Headlines

February 6, 2024 | finance.yahoo.com

SierraConstellation Partners Receives Industry Recognition for Work with Tricida

January 13, 2024 | es.investing.com

Tricida Inc (TCDAQ)

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

February 14, 2023 | finance.yahoo.com

Tricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Finance

February 3, 2023 | wsj.com

Firm Retention Summary: Tricida Inc.

November 15, 2022 | finance.yahoo.com

Tricida Announces Third Quarter 2022 Financial Results

November 2, 2022 | finance.yahoo.com

Tricida Provides Strategic Update

October 25, 2022 | markets.businessinsider.com

Why Tricida Stock Is Tanking Today

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

October 25, 2022 | bizjournals.com

Failed trial sends Peninsula kidney drug company's stock tumbling 94%

October 25, 2022 | msn.com

This Biotech Lost 95% in a Single Day. It Still Deserves Credit

October 25, 2022 | finance.yahoo.com

Tricida Shares Nosedive After Disappointing Data From Much Anticipated Kidney Disease Trial

October 24, 2022 | investorplace.com

Why Is Tricida (TCDA) Stock Down 90% Today?

October 24, 2022 | finance.yahoo.com

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

October 19, 2022 | seekingalpha.com

Tricida announces $125M debt facility - Seeking Alpha

October 19, 2022 | seekingalpha.com

Tricida enters $125M debt facility (NASDAQ:TCDA) - Seeking Alpha

October 19, 2022 | benzinga.com

Tricida Whale Trades For October 19 - Tricida (NASDAQ:TCDA) - Benzinga

October 19, 2022 | businesswire.com

Tricida Announces $125 Million Debt Facility with Hercules Capital - Business Wire

October 18, 2022 | benzinga.com

$2 Million Bet On Tricida? 3 Stocks Insiders Are Buying - Tricida (NASDAQ:TCDA), Riley Exploration Permia - Benzinga

October 14, 2022 | businesswire.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm - Business Wire

October 13, 2022 | stockhouse.com

2022-10-13 | NDAQ:TCDA | Press Release | Tricida Inc. - Stockhouse

October 13, 2022 | benzinga.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Te - Benzinga

October 7, 2022 | benzinga.com

Tricida Whale Trades Spotted

October 4, 2022 | uk.investing.com

$17 Million Bet On This Technology Stock? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UK

October 3, 2022 | finance.yahoo.com

Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022

October 3, 2022 | businesswire.com

Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022 - Business Wire

September 29, 2022 | uk.investing.com

Over $352 Million Bet On Occidental Petroleum? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UK

See More Headlines

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TCDA
CUSIP: N/A
CIK: 1595585
Web: www.tricida.com
Phone: (415) 429-7800
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-176,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -103.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.87
Quick Ratio: 4.87

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 55,670,000
Free Float: 35,851,000
Market Cap: $6.01 million
Optionable: Not Optionable
Beta: 0.22

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Gerrit Klaerner
President, Chief Executive Officer & Director
Geoffrey M. Parker
Chief Operating & Financial Officer, Executive VP
Dawn Parsell
Executive Vice President-Clinical Development
Robert McKague
Chief Compliance Officer, EVP & General Counsel
Annie Yoshiyama
Chief Accounting Officer & Vice President-Finance

Key Competitors

View All Competitors

TCDA Stock Analysis - Frequently Asked Questions

How were Tricida's earnings last quarter?: Tricida, Inc. (NASDAQ:TCDA) posted its earnings results on Monday, November, 8th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.09. During the same period in the prior year, the business posted ($1.55) EPS.
What is Gerrit Klaerner's approval rating as Tricida's CEO?: 2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Tricida own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).
When did Tricida IPO?: Tricida (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

This page (NASDAQ:TCDA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tricida (TCDA) Stock Price, News & Analysis

About Tricida Stock (NASDAQ:TCDA)

TCDA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TCDA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info